Sales & Marketing

Merging strengths of traditional behavioral and attitudinal research, capability enables pharmaceutical field teams to prioritize resources, targets, and outreach strategies.

Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.

FDA issues a sharp warning letter rebuking AcelRx Pharmaceuticals for its ”glib and simplistic” messaging on painkiller Dsuvia.

Melissa Fellner of AstraZeneca and Leonie Goddard of Veeva, talk to Pharm Exec about how AZ’s mission to transform its digital strategies to better connect with customers.

Adoption of digital by biopharma reps has added an element of flexibility to their engagement strategies, resulting in better communications with HCPs.

If telehealth is here to stay, how is the industry adjusting?

What the industry has learned navigating the pandemic and what the future holds for field teams.

Todd Nichols, chief commercial officer of Alkermes, gives his top three recommendations for going all-in to digitally transform the frontline sales team.

Understanding the changes in day-to-day life for physicians during COVID and how life science executives can address them.

Companies recognize that their success with digital starts with accurate customer data, but many struggle to manage the overwhelming volume of different data types from hundreds of sources.

Following the introduction this week MyVeeva for Doctors, Veeva’s Paul Shawah discusses the background to the product and the role biopharma companies will play in its ongoing development.

A deep-dive into how pharma companies can apply service operations principles to achieve a greater level of marketing and promotional review committee satisfaction.

Pharma marketers can use their "voice" to increase prominence in advertising.

Michael Wong speaks to Frank Cespedes, a senior lecturer at Harvard Business School, about how biopharma companies should be optimizing their sales and engagement activities for the 2020s.

A look at how UCB is utilizing dynamic targeting via AI to improve overall patient experience.

Brand positioning that targets HCPs is often irrelevant to the payer mindset. Fortunately, market access teams have an option, writes Ed Shankman.

Turning to a next-gen psoriasis treatment to help drive future fortunes.

While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.

Uncovering fish oil derivative’s benefit for heart health.

New hope accompanies overdue recognition in sickle cell disease fight.

Addressing the need for fast-acting therapy in treatment-resistant depression.

The world’s most expensive drug put in context.

The key factors behind the sector’s strong surge in new equity fundraisings.

How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.